โ Scribed by Abraham Zifroni; Raul C. Schiavi; Fenton Schaffner
No coin nor oath required. For personal study only.
The effects of nonalcoholic liver disease on sexual desire, arousal, activity, orgasmic function and satisfaction and serum testosterone levels were studied in 75 men with nonalcoholic liver disease. Each man was interviewed about his sexual behavior and problems and was asked to comment on whether he felt liver disease affected his sexual function. The average age of the patients was 49 yr, and a wide variety of liver diseases was represented. Child-Pugh grading was A in 51 patients, B in 18 and C in 6; the mean duration of liver disease was 8 yr. Sexual desire, arousal and activity of patients with grade A disease were within the ranges observed in studies of healthy men of comparable age. Diminished sexual desire was reported by 2% of grade A patients and 35% of grade B and C patients (p less than 0.005). Arousal problems were noted by 16% of grade A patients, 60% of grade B patients and 67% of C patients (p less than 0.005). Loss of erection and inability to regain erection were noted by 7%, 40% and 67% of grade A, B and C patients, respectively (p less than 0.01). Premature and retarded ejaculation were more frequent in patients classed in Child-Pugh grades B and C. Frequency of coitus and orgasm were significantly higher in grade A patients than in grade B and C patients. Total and free testosterone levels were (in nanograms per milliliter) A, 677/1.78; B, 416/1.06; and C, 178/0.43 (p less than 0.002). We concluded that Child-Pugh grade A nonalcoholic liver disease in men does not affect sexual desire, function or performance. Men with disease grades B and C have significant sexual dysfunction and significant reduction of both total and free testosterone levels.
๐ SIMILAR VOLUMES
Li et al. have analyzed golgi phosphoprotein 2 (GOLPH2) serum levels in a cohort of patients with liver cirrhosis, healthy controls, and patients with hepatocellular carcinoma (HCC). They found elevated serum levels of GOLPH2 (sGOLPH2) in early HCC cases. From their findings, the authors conclude th
We read with interest the articles on hepatic venous pressure gradient (HVPG) measurements. [1][2][3] We fully agree on the need to standardize HVPG measurements to get reliable, reproducible, and useful data. 1 We also agree that before recommending such measurements in clinical practice, it is nec
Nonalcoholic fatty liver disease (NAFLD) has been consistently found to be associated with features of the metabolic syndrome (MS), a condition carrying a high risk of cardiovascular events. The present study aimed to determine whether, in children and adolescents, NAFLD is atherogenic beyond its as
We congratulate Fracanzani and colleagues 1 on their insightful article identifying factors associated with severe liver disease in patients with nonalcoholic fatty liver disease (NAFLD) and normal aminotransferase levels. First, the authors have convincingly demonstrated that normal alanine aminotr
It is uncertain whether patients with nonalcoholic fatty liver disease (NAFLD) and normal alanine aminotransferase (ALT) have a milder disease and should undergo liver biopsy. We reviewed the histological data of 458 Italian patients with NAFLD in whom liver biopsy was indicated by altered liver enz